Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the UK and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR)

Autor: Yiu, Z. Z. N., Ashcroft, D. M., Evans, I, McElhone, K., Lunt, M., Smith, C. H., Walton, S., Murphy, R., Reynolds, N. J., Ormerod, A. D., Griffiths, C. E. M., Warren, R. B., Irshad, Shamila, Wilde, Victoria, Tahir, Saliha, Ali, Hassan, Mason, Kayleigh, Hussain, Sagair, Granger, Emily, Chalmers, Robert, Flohr, Carsten, Watson, Karen, Prieto-Merino, David, Barker, Jonathan, Benham, Marilyn, Burden, David, Griffiths, Christopher, Kirby, Brian, Lawson, Linda, Ormerod, Anthony, Owen, Caroline, Reynolds, Nick, Warren, Richard

Publikováno v: Yiu, Z Z N, Ashcroft, D M, Evans, I, McElhone, K, Lunt, M, Smith, C H, Walton, S, Murphy, R, Reynolds, N J, Ormerod, A D, Griffiths, C E M, Warren, R B, Irshad, S, Wilde, V, Tahir, S, Ali, H, Mason, K, Hussain, S, Granger, E, Chalmers, R, Flohr, C, Watson, K, Prieto-Merino, D, Barker, J, Benham, M, Burden, D, Griffiths, C, Kirby, B, Lawson, L, Ormerod, A, Owen, C, Reynolds, N, Smith, C H & Warren, R 2019, ' Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the UK and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR) ', British Journal of Dermatology, vol. 180, no. 2, pp. 329-337 . https://doi.org/10.1111/bjd.17036

BackgroundPatients with psoriasis and clinicians are concerned that infliximab may be associated with a risk of serious infections.ObjectivesTo compare the risk of serious infections associated with infliximab in patients with chronic plaque psoriasi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2761::50c4559e45eb718290e28385f0776943
https://kclpure.kcl.ac.uk/en/publications/bc944fb7-066c-46c4-9107-b0e81596c22e